{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:34:14Z","timestamp":1789533254156,"version":"build-2803163510"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T00:00:00Z","timestamp":1693440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012542","name":"Sichuan Province Science and Technology Support Program","doi-asserted-by":"publisher","award":["2022YFS0191"],"award-info":[{"award-number":["2022YFS0191"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Zanubrutinib is a Bruton tyrosine kinase (BTK) inhibitor used in B cell malignancy treatment and is generally well tolerated in most patients. Zanubrutinib-induced aseptic meningitis is currently not reported. Herein, we present the first case of zanubrutinib-induced aseptic meningitis. A 33-year-old woman was diagnosed with relapsed\/refractory follicular lymphoma and subsequently developed aseptic meningitis after receiving zanubrutinib treatment. We reviewed the literature and uncovered the lack of current reports on zanubrutinib or other BTK inhibitor-induced aseptic meningitis. Moreover, we summarized cases on aseptic meningitis induced by common chemotherapy and targeted drugs used for hematological diseases. Drug-induced aseptic meningitis (DIAM) is a drug-induced meningeal inflammation. The possible pathogenesis is the direct stimulation of the meninges via intrathecal injection of chemotherapy drugs and immune hypersensitivity response caused by immunosuppressive drugs. It is more common in women with immune deficiency and mainly manifests as persistent headache and fever. Cerebrospinal fluid examinations mainly demonstrate a significant increase in cells and proteins. DIAM diagnosis needs to exclude bacterial, fungal, viral, and tuberculosis infections; neoplastic meningitis; and systemic diseases involving the meninges. The prognosis of DIAM is usually favorable, and physicians should detect and stop the causative drug. In conclusion, zanubrutinib-induced aseptic meningitis is a rare but serious complication, and physicians should be promptly aware of this adverse event to avoid serious consequences.<\/jats:p>","DOI":"10.3389\/fphar.2023.1242491","type":"journal-article","created":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T11:19:01Z","timestamp":1693480741000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Zanubrutinib-induced aseptic meningitis: a case report and literature review"],"prefix":"10.3389","volume":"14","author":[{"given":"Jinjun","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenlu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,8,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1182\/blood.2019004195","article-title":"Drug-induced aseptic meningitis in a Ph+ ALL patient with meningeal involvement","volume":"136","author":"Beaumont","year":"2020","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ncl.2021.08.006","article-title":"Infectious meningitis and encephalitis","volume":"40","author":"Bystritsky","year":"2022","journal-title":"Neurol. Clin."},{"key":"B3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41582-020-00427-y","article-title":"Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease","volume":"17","author":"Cortese","year":"2021","journal-title":"Nat. Rev. Neurol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s40265-021-01482-5","article-title":"Orelabrutinib: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"B5","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/0959-8049(92)90418-2","article-title":"Meningeal fluid granulocytosis after cytarabine","volume":"28","author":"Flasshove","year":"1992","journal-title":"Eur. J. Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/s1474-4422(15)00111-8","article-title":"Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions","volume":"14","author":"Fugate","year":"2015","journal-title":"Lancet Neurol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1056\/NEJMra2114482","article-title":"Posterior reversible encephalopathy syndrome","volume":"388","author":"Geocadin","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1158\/2159-8290.Cd-17-0613","article-title":"Ibrutinib unmasks critical role of Bruton tyrosine kinase in primary CNS lymphoma","volume":"7","author":"Grommes","year":"2017","journal-title":"Cancer Discov."},{"key":"B9","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/qco.0000000000000922","article-title":"Viral meningitis and encephalitis: an update","volume":"36","author":"Gundamraj","year":"2023","journal-title":"Curr. Opin. Infect. Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1001\/jama.2022.20521","article-title":"Progress and challenges in bacterial meningitis: A review","volume":"328","author":"Hasbun","year":"2022","journal-title":"Jama"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1007\/s00277-014-2074-4","article-title":"NKT cell-infiltrating aseptic meningitis on the central nervous system in Philadelphia chromosome-positive acute lymphoblastic leukemia treated with dasatinib","volume":"93","author":"Imataki","year":"2014","journal-title":"Ann. Hematol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/ejh.13204","article-title":"Haploidentical transplantation using low-dose alemtuzumab: comparison with haploidentical transplantation using low-dose thymoglobulin","volume":"102","author":"Kako","year":"2019","journal-title":"Eur. J. Haematol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s12272-019-01124-1","article-title":"Development of BTK inhibitors for the treatment of B-cell malignancies","volume":"42","author":"Kim","year":"2019","journal-title":"Arch. Pharm. Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.3109\/10428190903186486","article-title":"A phase I\/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia","volume":"50","author":"Lin","year":"2009","journal-title":"Leuk. Lymphoma"},{"key":"B15","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1182\/hematology.2020000118","article-title":"Managing toxicities of Bruton tyrosine kinase inhibitors","volume":"2020","author":"Lipsky","year":"2020","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"B16","first-page":"314","article-title":"Aseptic and bacterial meningitis: evaluation, treatment, and prevention","volume":"96","author":"Mount","year":"2017","journal-title":"Am. Fam. Physician"},{"key":"B17","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","article-title":"Role of Bruton's tyrosine kinase in B cells and malignancies","volume":"17","author":"Pal Singh","year":"2018","journal-title":"Mol. Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/00006454-200101000-00022","article-title":"Aseptic meningitis in a child after systemic treatment with high dose cytarabine","volume":"20","author":"Pease","year":"2001","journal-title":"Pediatr. Infect. Dis. J."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e333","DOI":"10.1016\/j.clml.2018.05.018","article-title":"Aseptic meningitis as a complication of daratumumab therapy","volume":"18","author":"Reddy","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"B20","article-title":"Preliminary results of orelabrutinib concentrations in peripheral blood and cerebrospinal fuid in patients with relapsed\/refractory primary or secondary CNS lymphoma","volume-title":"The 24th national congress of clinical oncology","author":"Song","year":"2021"},{"key":"B21","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s40265-019-01252-4","article-title":"Zanubrutinib: first approval","volume":"80","author":"Syed","year":"2020","journal-title":"Drugs"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1182\/bloodadvances.2021005621","article-title":"Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies","volume":"6","author":"Tam","year":"2022","journal-title":"Blood Adv."},{"key":"B23","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.neurol.2019.07.005","article-title":"Aseptic meningitis","volume":"175","author":"Tattevin","year":"2019","journal-title":"Rev. Neurol. Paris."},{"key":"B24","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/j.0954-6820.1986.tb02801.x","article-title":"Acute meningitis and cerebellar dysfunction complicating high-dose cytosine arabinoside therapy","volume":"220","author":"Thordarson","year":"1986","journal-title":"Acta Med. Scand."},{"key":"B25","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/sj.leu.2402063","article-title":"Cytarabine-induced aseptic meningitis","volume":"15","author":"van den Berg","year":"2001","journal-title":"Leukemia"},{"key":"B26","doi-asserted-by":"publisher","first-page":"32532","DOI":"10.18632\/oncotarget.8687","article-title":"Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia","volume":"7","author":"Vey","year":"2016","journal-title":"Oncotarget"},{"key":"B27","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/fcp.12349","article-title":"Drug-induced aseptic meningitis: A mini-review","volume":"32","author":"Yelehe-Okouma","year":"2018","journal-title":"Fundam. Clin. Pharmacol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"760405","DOI":"10.3389\/fonc.2021.760405","article-title":"Preliminary evaluation of zanubrutinib-containing regimens in dlbcl and the cerebrospinal fluid distribution of zanubrutinib: A 13-case series","volume":"11","author":"Zhang","year":"2021","journal-title":"Front. Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1126235","DOI":"10.3389\/fphar.2023.1126235","article-title":"Posterior reversible encephalopathy syndrome after anlotinib treatment for small cell lung cancer: A case report and literature review","volume":"14","author":"Zou","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1093\/neuonc\/nox115","article-title":"Neurological complications of new chemotherapy agents","volume":"20","author":"Zukas","year":"2018","journal-title":"Neuro Oncol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1242491\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T11:19:03Z","timestamp":1693480743000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1242491\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,31]]},"references-count":30,"alternative-id":["10.3389\/fphar.2023.1242491"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1242491","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,31]]},"article-number":"1242491"}}